Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- 3 Trade Groups Vehemently Oppose “Huge Seller” Drug Re-Pricing, Say It Will Hobble Innovation
December 10, 2015
- Industry Opposes Expanded Price Cuts under Z2 Rule, Calls for Retention of 60% Pricing Rule for New Injectable, Topical Generics
December 10, 2015
- LDP Budget Debate in Homestretch; Govt Eyes “Huge Sellers”, Generics, Z2 to Squeak Out Funds for Upping Physician Fees
December 9, 2015
- MHLW’s Failure to Detect Kaketsuken’s 40-Year Cover-Up Regrettable: Shiozaki
December 9, 2015
- Editor’s Pick: Five Healthcare Policy News Headlines for November
December 8, 2015
- MHLW Announces Basic Policy for FY2016 Medical Fee Reform
December 8, 2015
- PMDA to Begin Unannounced Regular Inspections in Wake of GMP Violations by Kaketsuken
December 8, 2015
- MHLW Proposes Continuing Penalty Fee Cuts for Hospitals, Pharmacies with Revised Scope
December 7, 2015
- NHI-Market Price Gap of 8.8% Reported to Chuikyo; Generic Share at 56.2% in September
December 7, 2015
- MHLW Calls for 50% Pricing Rule for First Generics, 40% Rule for 10-Plus Oral Generics
December 4, 2015
- New HTA Scheme Should Only Cover Big-Selling Products Given Big Premiums: JPMA Chief
December 4, 2015
- Chuikyo Subcommittee Agrees on Scope of “Essential Drugs”; Trial Run of Innovation Premium to Continue
December 4, 2015
- Chuikyo Basically OKs 2-Tiered Re-Pricing for Huge Seller Drugs; Sovaldi Almost Certain to Face Cut
December 3, 2015
- Probe Finds Kaketsuken’s GMP Violations “Extremely Malicious”, MHLW to Impose Penalty
December 3, 2015
- NHI-Market Price Gap at 8.8%, 6.8% Price Cut Expected in FY2016 Revision
December 3, 2015
- Generic Replacement Rate Applied to Z2 Rule to Be Hiked 10%
December 3, 2015
- Revamped Sakigake Pricing Premium to Grant Maximum Premium Rate of 20%: Chuikyo Subcommittee
December 3, 2015
- Interstitial Pneumonia Added to ADR List for Daklinza, Sunvepra
December 2, 2015
- MHLW Discussing Use of Disease Registry as Substitute for Control Groups; Could Be “One Means of Evaluation” in Trials for Rare Diseases
December 2, 2015
- MHLW Study Group to Survey Unvaccinated Teens to Resolve HPV Issues
December 1, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…